'DEEP Symposium' held in Busan, drawing 56 medical professionals and expert speakers
Showcasing clinical applications of Nabota, V-Olet, Riallo Inject Fine, Douce, and Declassi CaHA
Discussing patient-specific treatment plans and methodologies through clinical lectures, live demonstrations, and panel debates
Daewoong Pharmaceutical (069620) (CEOs Park Sung-soo and Lee Chang-jae) and DNC Aesthetics (CEO Yoo Hyun-seung) have shared comprehensive aesthetic strategies ranging from skin condition improvement to facial contouring and lifting. The companies presented methodologies for selecting and combining products tailored to individual patients' skin conditions, facial structures, and treatment objectives, backed by practical clinical cases.
The two companies announced that they held the "DEEP Symposium" over a two-day run from the 24th to the 25th at Lotte Hotel Busan. Held under the theme "From Skin to Shape: A Full-Face Combination Strategy," the event was attended by medical professionals and guest speakers utilizing the medical aesthetic portfolios of both firms.
DEEP is an acronym for the "Daewoong·DNC Aesthetics Medical-AEsthetic Expert Program," a specialized educational initiative designed by the companies to share treatment trends and clinical experiences with healthcare practitioners.
The symposium covered practical applications of the botulinum toxin product "Nabota," the fat-dissolving injection "V-Olet," the ECM-based "Riallo Inject Fine," the lifting thread "Douce," and the calcium hydroxylapatite (CaHA)-based "Declassi CaHA." Through a combination of lectures, panel discussions, and live demonstrations, participants explored treatment planning and application methods that factor in the distinct characteristics of each product alongside patient-specific improvement goals.
The first day featured lectures and discussions centered on skin revitalization and facial contouring. Son Moo-hyun, CEO of Cheongdam FnB Clinic, presented combination treatment strategies utilizing Nabota, V-Olet, and Riallo Inject Fine. Yoon Hyun-seung, director of Mimi-sum Clinic's Gimhae branch, elaborated on the process of establishing patient-specific treatment regimens and sharing practical application experiences based on actual clinical cases.
[Photo caption = Dual live broadcast of the Daewoong Pharmaceutical and DNC Aesthetics 'DEEP Symposium']
A panel discussion featuring both speakers explored product combinations, application strategies by facial region, and key considerations for combination treatments. Attending medical professionals analyzed product characteristics and utility options based on diverse scenarios, exchanging hands-on procedural know-how for clinical practice.
The second day featured a lecture by Park Tae-hyung, director of Gangnam Skiniq Clinic, followed by a live treatment demonstration by Kim Seo-hwan, director of Gwangju Petit 2.7 Clinic.
Dr. Park outlined clinical approaches addressing facial contour changes and secondary patient enhancement demands following energy-based device (EBD) procedures. He also shared case studies and procedural experiences combining Douce, Declassi CaHA, and Riallo Inject Fine.
Dr. Kim demonstrated product application methods and procedural techniques via a dual live broadcast. Attendees were able to observe firsthand how the strategies discussed in the lectures translate into actual clinical practice.
Yoon Jun-soo, head of Daewoong Pharmaceutical's Nabota Business Division, remarked, "In combination treatments, it is crucial to understand the characteristics of each product and determine the appropriate application for each patient. We will continue to provide educational programs combining clinical lectures, live demonstrations, and discussions to assist medical professionals in product selection and treatment planning."
Yoo Hyun-seung, CEO of DNC Aesthetics, stated, "The core of combination therapy lies in accurately assessing the improvements required by the patient and selecting the corresponding products and procedures. Building on the product lineups of Daewoong Pharmaceutical and DNC Aesthetics, we will continue our educational initiatives to empower medical professionals to review diverse approaches and share clinical insights."
[Photo caption = Panel discussion at the Daewoong Pharmaceutical and DNC Aesthetics 'DEEP Symposium']
